Delivery of therapeutic oligonucleotides in nanoscale

Author:

Wu LeiORCID,Zhou WenhuiORCID,Lin Lihua,Chen Anhong,Feng Jing,Qu Xiangmeng,Zhang HongboORCID,Yue JunORCID

Funder

Sun Yat-Sen University

Academy of Finland

Science and Technology Planning Project of Shenzhen Municipality

Sigrid Juseliuksen Saatio

Guangdong Provincial Natural Science Foundation

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Biomedical Engineering,Biomaterials,Biotechnology

Reference420 articles.

1. Therapeutic oligonucleotides: state of the art;Smith,2019

2. Chapter five - recent advances in nanoparticle-based cancer drug and gene delivery;Amreddy,2018

3. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with aids;Am. J. Ophthalmol.,2002

4. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers;Chi;Ann. Oncol.,2016

5. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors;Schultheis;J. Clin. Oncol.,2014

Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3